论文部分内容阅读
随着免疫细胞生物学及免疫分子生物学的高速发展,细胞介导的过继免疫治疗已成为肿瘤患者放疗、化疗后辅助治疗的重要手段之一,作为抗肿瘤免疫治疗的重要手段。目前已用于临床的过继免疫治疗效应细胞有:淋巴因子激活的杀伤细胞(lymphokine-activated killercells,LAK),肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TIL),细胞毒性T淋巴细胞(cytotoxic Tlymphocytes,CTL)、细胞因子诱导的杀伤细胞(cytokine-induced killercells,CIK)和树突状细胞(dendritic cells,DC)等。CIK是
With the rapid development of immune cell biology and immune molecular biology, cell-mediated adoptive immunotherapy has become one of the important means of adjuvant therapy for radiotherapy and chemotherapy in cancer patients and as an important means of anti-tumor immunotherapy. Currently used in clinical adoptive immunotherapy effector cells are: lymphokine-activated killer cells (LAK), tumor infiltrating lymphocytes (TIL), cytotoxic T lymphocytes (cytotoxic T lymphocytes (CTL ), Cytokine-induced killer cells (CIK) and dendritic cells (DCs). CIK is